Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.
Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.